HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Lupin receives tentative USFDA approval for Apixaban Tablets
Dec-10-2018

Lupin has received tentative approval for its Apixaban Tablets, 2.5 mg and 5 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Bristol-Myers Squibb Company's Eliquis Tablets, 2.5 mg and 5 mg.

Lupin's Apixaban Tablets, 2.5 mg and 5mg is the generic version of Bristol-Myers Squibb Company's Eliquis Tablets, 2.5 mg and 5 mg.

Eliquis Tablets, 2.5 mg and 5 mg had annual sales of approximately $6366 million in the US (IQVIA MAT September 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

  RELATED NEWS >>